{"id":231855,"date":"2026-02-22T13:05:18","date_gmt":"2026-02-22T19:05:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/engineered-nanoparticles-could-deliver-better-targeted-cancer-treatment-to-lymph-nodes"},"modified":"2026-02-22T13:05:18","modified_gmt":"2026-02-22T19:05:18","slug":"engineered-nanoparticles-could-deliver-better-targeted-cancer-treatment-to-lymph-nodes","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/engineered-nanoparticles-could-deliver-better-targeted-cancer-treatment-to-lymph-nodes","title":{"rendered":"Engineered nanoparticles could deliver better targeted cancer treatment to lymph nodes"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/engineered-nanoparticles-could-deliver-better-targeted-cancer-treatment-to-lymph-nodes.jpg\"><\/a><\/p>\n<p>Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study. The work is <a href=\"https:\/\/pnas.org\/doi\/10.1073\/pnas.2519625123\" target=\"_blank\">published<\/a> in the journal Proceedings of the National Academy of Sciences.<\/p>\n<p>The <a href=\"https:\/\/medicalxpress.com\/news\/2025-09-lymph-nodes-key-successful-cancer.html?utm_source=embeddings&utm_medium=related&utm_campaign=internal\" rel=\"related\" target=\"_blank\">experimental approach<\/a> is designed to treat cancer that has spread to the lymph nodes, a difficult-to-treat stage of the disease. Today, most immunotherapies are delivered by intravenous (IV) infusion and circulate throughout the body. This can trigger immune responses in healthy tissues, leading to serious side effects.<\/p>\n<p>\u201cSome immunotherapies cause such severe side effects that clinicians are forced to lower the dose, making treatment less effective,\u201d said senior author Guojun Chen, Assistant Professor in McGill\u2019s Department of Biomedical Engineering and member of the Goodman Cancer Institute. \u201cOur approach could allow for higher, more effective doses while limiting toxicity, which is a major goal in cancer treatment.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study. The work is published in the journal Proceedings of the National Academy of Sciences. The experimental approach is designed to treat [\u2026]<\/p>\n","protected":false},"author":732,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,38,4],"tags":[],"class_list":["post-231855","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-engineering","category-nanotechnology"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/732"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=231855"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231855\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=231855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=231855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=231855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}